| Title |
Circulating vascular endothelial growth factor receptor 2/pAkt-positive cells as a functional pharmacodynamic marker in metastatic colorectal cancers treated with antiangiogenic agent
|
|---|---|
| Published in |
Investigational New Drugs, April 2012
|
| DOI | 10.1007/s10637-012-9817-7 |
| Pubmed ID | |
| Authors |
Sang Joon Shin, Jee Won Hwang, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Hyun Cheol Chung |
| Abstract |
The anti-vascular endothelial growth factor (VEGF) antibody bevacizumab has received considerable attention as a first-line treatment of advanced colorectal cancers. Difficulties associated with effectively monitoring the activity of this drug have prompted us to seek a pharmacodynamic marker suitable for defining the optimum biological dose and schedule of bevacizumab administration against colon cancer in early clinical trials. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 17 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Korea, Republic of | 1 | 6% |
| Unknown | 16 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 6 | 35% |
| Researcher | 3 | 18% |
| Student > Bachelor | 3 | 18% |
| Other | 1 | 6% |
| Lecturer | 1 | 6% |
| Other | 2 | 12% |
| Unknown | 1 | 6% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 53% |
| Agricultural and Biological Sciences | 4 | 24% |
| Biochemistry, Genetics and Molecular Biology | 2 | 12% |
| Unknown | 2 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 April 2012.
All research outputs
#20,156,537
of 22,664,644 outputs
Outputs from Investigational New Drugs
#975
of 1,164 outputs
Outputs of similar age
#148,169
of 163,320 outputs
Outputs of similar age from Investigational New Drugs
#15
of 15 outputs
Altmetric has tracked 22,664,644 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,164 research outputs from this source. They receive a mean Attention Score of 4.7. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,320 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.